Zydus Lifesciences Ltd (CADILAHC) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally.
Total Assets Chart for Zydus Lifesciences Ltd
Zydus Lifesciences Ltd (CADILAHC) total assets for FY2021 were INR 238.8B, a 0.8% change from FY2020. Zydus Lifesciences Ltd's total assets grew from INR 13.4B in 2004 to INR 238.8B in 2021 (1679.4% over 17 years). Total assets compound annual growth rate: 5-year CAGR of 19.0%, 10-year CAGR of 18.0%.
Total Assets (Indian Rupees)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ₹354.27B
- Implied Share Price
- ₹346.05
- Enterprise Value
- ₹367.06B
- Revenue (TTM)
- ₹157.61B
- EBITDA
- ₹33.88B
- Profit Margin
- 30.26%
- Trailing P/E
- 7.43
- Forward P/E
- 20.20
- Price/Book (MRQ)
- 2.25
- Price/Sales (TTM)
- 2.25
- EV/EBITDA
- 10.64
- EV/Revenue
- 2.39
- Dividend Yield
- 0.00%
- Book Value
- ₹158.15
- Free Cash Flow (FY2021)
- ₹24.39B
- Free Cash Flow Yield
- 6.88%
Snapshot as of 5th September 2023 — not point-in-time controlled, may lag the live market by a few days.